|October 15, 2013|
|08:44 EDT||VRTX, JNJ||Incivek ex-US sales missed consensus, says Deutsche Bank|
Deutsche Bank notes Johnson & Johnson (JNJ) this morning reported Incivek ex-U.S. sales of $76M, below the consensus of $141M. Deutsche says Vertex (VRTX) receives around 25% royalties on ex-U.S. sales which suggests implied Q3 royalties at $20M, below the $40M consensus. The firm adds that it will be looking for details on the weakness during J&J's conference call.
News For VRTX;JNJ From The Last 14 Days
Check below for free stories on VRTX;JNJ the last two weeks.
|December 5, 2013|
|07:59 EDT||JNJ||Cooper Companies added to Select List at Stifel|
Stifel added Cooper Companies (COO) to its Select List after surveying 36 optometry practices in the U.K. The firm reports that Cooper's new silicone hydrogel daily lens, MyDay, appears to be performing well in the country, and is ranked ahead of J&J's (JNJ) competing TruEye by optometrists there. The firm keeps a $150 price target and Buy rating on Cooper.
|December 4, 2013|
|16:51 EDT||JNJ||Johnson & Johnson unit to pay $1.25M to settle with FDA|
The U.S. Food and Drug Administration has reached a $1.25M settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon, a Johnson & Johnson company, and two of ASP’s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products. The settlement requires ASP to pay $1.2M, company president Bernard Zovighian to pay $30,000, and company VP of quality and regulatory compliance Richard Alberti to pay $20,000. Reference Link
|11:47 EDT||VRTX||Vertex, Regeneron speculated to be merger targets, TheStreet says|
Among the predictions for the biotech sector in 2014 made by David Sobek of TheStreet.com was a call for "at least two" mergers between large-cap companies. Sobek predict Sanofi (SNY) will buy Regeneron (REGN) and that Bristol-Myers Squibb (BMY) will acquire Vertex Pharmaceuticals (VRTX). Reference Link
|December 3, 2013|
|08:56 EDT||JNJ||LabCorp announces availability of enhanced HCV GenoSure NS3/4|
Laboratory Corporation (LH) announced the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics’ (JNJ) OLYSIO, which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
|December 2, 2013|
|07:52 EDT||VRTX||Deutsche Bank to host a conference|
Subscribe for More Information
|November 27, 2013|
|13:21 EDT||JNJ||J&J may pay $1B in medical costs under hip settlement, Bloomberg says|
Johnson & Johnson may have to pay up to $1B to insurers who covered the medical costs of removing its recalled hip implants under the settlement announced previously, says Bloomberg. Reference Link